Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients
Brain and Behavior · 2023
DOI: 10.1002/brb3.3327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2023. Verfasst von Marlene Tahedl und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Neurodegenerative Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Objective
Cortical gray matter (GM) atrophy plays a central role in multiple sclerosis (MS) pathology. However, it is not commonly assessed in clinical routine partly because a number of methodological problems hamper the development of a robust biomarker to quantify GM atrophy. In previous work, we have demonstrated the clinical utility of the “mosaic approach” (MAP) to assess individual GM atrophy in the motor neuron disease spectrum and frontotemporal dementia. In this study, we investigated the clinical utility of MAP in MS, comparing this novel biomarker to existing methods for computing GM atrophy in single patients. We contrasted the strategies based on correlations with established biomarkers reflecting MS disease burden.
Methods
We analyzed T1‐weighted MPRAGE magnetic resonance imaging data from 465 relapsing‐remitting MS patients and 89 healthy controls. We inspected how variations of existing strategies to estimate individual GM atrophy (“standard approaches”) as well as variations of MAP (i.e., different parcellation schemes) impact downstream analysis results, both on a group and an individual level. We interpreted individual cortical disease burden as single metric reflecting the fraction of significantly atrophic data points with respect to the control group. In addition, we evaluated the correlations to lesion volume (LV) and Expanded Disability Status Scale (EDSS).
Results
We found that the MAP method yielded highest correlations with both LV and EDSS as compared to all other strategies. Although the parcellation resolution played a minor role in terms of absolute correlations with clinical variables, higher resolutions provided more clearly defined statistical brain maps which may facilitate clinical interpretability.
Conclusion
This study provides evidence that MAP yields high potential for a clinically relevant biomarker in MS, outperforming existing methods to compute cortical disease burden in single patients. Of note, MAP outputs brain maps illustrating individual cortical disease burden which can be directly interpreted in daily clinical routine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany.
- Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany.
ORCID-Profile: Marlene Tahedl
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Tahedl, M., Wiltgen, T., Voon, C. C., Berthele, A., Kirschke, J. S., Hemmer, B., Mühlau, M., Zimmer, C., & Wiestler, B. (2023). Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients. Brain and Behavior. https://doi.org/10.1002/brb3.3327
Vancouver
Tahedl M, Wiltgen T, Voon CC, Berthele A, Kirschke JS, Hemmer B, et al. Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients. Brain and Behavior. 2023. doi:10.1002/brb3.3327
BibTeX
@article{Tahedl2023,
author = {Tahedl, Marlene and Wiltgen, Tun and Voon, Cui Ci and Berthele, Achim and Kirschke, Jan S and Hemmer, Bernhard and Mühlau, Mark and Zimmer, Claus and Wiestler, Benedikt},
title = {Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients},
journal = {Brain and Behavior},
year = {2023},
doi = {10.1002/brb3.3327}
}
EUVIMED